## Erik Berglund

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/980893/publications.pdf Version: 2024-02-01



FDIK REDCLUND

#	Article	IF	CITATIONS
1	Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity. Frontiers in Immunology, 2021, 12, 599526.	4.8	5
2	Strategies for Liver Transplantation Tolerance. International Journal of Molecular Sciences, 2021, 22, 2253.	4.1	17
3	Direct interaction of the ATP-sensitive K+ channel by the tyrosine kinase inhibitors imatinib, sunitinib and nilotinib. Biochemical and Biophysical Research Communications, 2021, 557, 14-19.	2.1	4
4	Organ transplants of the future: planning for innovations including xenotransplantation. Transplant International, 2021, 34, 2006-2018.	1.6	11
5	Pharmacokinetic and pharmacodynamic study of a clinically effective anti D2 monoclonal antibody. Scandinavian Journal of Immunology, 2020, 91, e12839.	2.7	9
6	Safety and pharmacodynamics of antiâ€ <scp>CD</scp> 2 monoclonal antibody treatment in cynomolgus macaques – an experimental study. Transplant International, 2020, 33, 98-107.	1.6	7
7	Impact of CMV Reactivation, Treatment Approaches, and Immune Reconstitution in a Nonmyeloablative Tolerance Induction Protocol in Cynomolgus Macaques. Transplantation, 2020, 104, 270-279.	1.0	3
8	Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Frontiers in Immunology, 2020, 11, 592553.	4.8	12
9	Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors. Cancer Immunology, Immunotherapy, 2020, 69, 2393-2401.	4.2	18
10	CD2 Immunobiology. Frontiers in Immunology, 2020, 11, 1090.	4.8	68
11	Phase I trial evaluating safety and efficacy of intratumorally administered allogeneic monocyte-derived cells (ilixadencel) in advanced gastrointestinal stromal tumors Journal of Clinical Oncology, 2020, 38, 15-15.	1.6	2
12	Biochemical Inhibition of DOG1/TMEM16A Achieves Antitumoral Effects in Human Gastrointestinal Stromal Tumor Cells <i>In Vitro</i> . Anticancer Research, 2019, 39, 3433-3442.	1.1	15
13	Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight, 2018, 3, .	5.0	54
14	Liver transplantation for acute liver failure – a 30-year single center experience. Scandinavian Journal of Gastroenterology, 2018, 53, 876-882.	1.5	8
15	miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. Experimental Cell Research, 2018, 371, 287-296.	2.6	27
16	Assessing the purity of regulatory T cells: A humble reminder. Cytotherapy, 2017, 19, 329-332.	0.7	0
17	Secretome protein signature of human gastrointestinal stromal tumor cells. Experimental Cell Research, 2015, 336, 158-170.	2.6	6
18	Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells. Anti-Cancer Drugs, 2014, 25, 415-422.	1.4	13

#	Article	IF	CITATIONS
19	Functional role of the Ca2+-activated Clâ^' channel DOG1/TMEM16A in gastrointestinal stromal tumor cells. Experimental Cell Research, 2014, 326, 315-325.	2.6	49
20	Evidence for Ca2+-regulated ATP release in gastrointestinal stromal tumors. Experimental Cell Research, 2013, 319, 1229-1238.	2.6	13
21	PRE-OPERATIVE SPIROMETRY IN THORACIC SURGERY. Acta Anaesthesiologica Scandinavica, 1965, 9, 57-64.	1.6	12